Lantern Pharma's Participation in ThinkEquity Conference: Key Investor Information

What is the main announcement in this content?

Lantern Pharma’s management team will present at the ThinkEquity Conference on Thursday, October 30, 2025, at 11:30 a.m. ET at the Mandarin Oriental in New York to discuss their AI-driven oncology drug discovery platform and development pipeline.

What does Lantern Pharma specialize in?

Lantern Pharma is an artificial intelligence company focused on developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery using their proprietary AI and machine learning platform called RADR®.

What is RADR® and what capabilities does it have?

RADR® is Lantern Pharma’s proprietary AI and machine learning platform that leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar problems in oncology drug development.

What is the significance of Lantern Pharma’s drug pipeline?

Lantern Pharma’s AI-driven pipeline includes a Phase 2 clinical program, multiple Phase 1 clinical trials, and an antibody-drug conjugate program, with an estimated combined annual market potential of over $15 billion USD and potential to provide life-changing therapies to hundreds of thousands of cancer patients worldwide.

Where can investors find more information about Lantern Pharma?

The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN, and the full press release about the conference presentation can be viewed at https://ibn.fm/QSF41.

What types of cancers does Lantern Pharma’s pipeline address?

Lantern Pharma’s growing pipeline of therapies spans multiple cancer indications, including both solid tumors and blood cancers, along with an antibody-drug conjugate (ADC) program.

Why is Lantern Pharma’s approach to drug discovery considered innovative?

Lantern Pharma’s approach is innovative because it uses AI and machine learning to accelerate oncology drug development, significantly reducing costs and timelines while leveraging world-class scientific advisors and collaborators to develop targeted cancer therapies.

What is the current stage of Lantern Pharma’s clinical development programs?

Lantern Pharma’s lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials, indicating they have advanced candidates moving through the clinical development process.